United States Ophthalmic Market to reach USD 33.97 Bn by 2032

The United States ophthalmic market is expected to be valued at approximately USD 18.82 billion in 2025 and reach USD 33.97 billion by 2032, exhibiting a CAGR of 18.82% during the forecast period. This growth is primarily driven by the increasing prevalence of eye diseases such as cataracts, glaucoma, and age-related macular degeneration, coupled with a growing geriatric population susceptible to these conditions. More than four million Americans are living with glaucoma, over 2 million of whom—aged 40 and older—are affected by its most common form, open-angle glaucoma. It is mostly associated with increased pressure on and inside eyes. Additionally, rising healthcare expenditures and increased awareness about early diagnosis and treatment options are fueling demand for ophthalmic products and services across the country.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/united-states-ophthalmic-market

The United States ophthalmic market growth is primarily driven by modern lifestyle factors, such as increased screen time and constant exposure to digital devices, resulting in a rise in conditions like digital eye strain and dry eye syndrome. According to a HealthArc report in October 2024, Americans now spend an average of 7 hours and 3 minutes per day using internet-connected devices, with nearly equal time spent on mobile devices (3 hours 30 minutes) and computers (3 hours 34 minutes).

Additionally, the growth of teleophthalmology and remote patient monitoring (RPM) is enhancing access to eye care, particularly in underserved communities. These technologies facilitate early detection and continuous disease management, further fueling the market expansion. The number of patients using RPM in the U.S. grew from 23 million in 2020 to 30 million in 2024, with projections suggesting this number could reach 70.6 million by the end of 2025.

This rapid adoption of RPM technologies highlights the increasing popularity of digital health solutions, benefiting both healthcare providers and patients. As a result, the integration of teleophthalmology services is expected to play a key role in the continued growth of the ophthalmic market.

Innovations in ophthalmic procedures, such as femtosecond laser-assisted cataract surgery and micro-invasive glaucoma surgery (MIGS), are gaining traction. These surgeries offer fast recovery and better patient outcomes, leading to higher adoption rates. In early 2024, several glaucoma specialists in Texas began utilizing next-generation MIGS devices that allow for more effective intraocular pressure reduction with minimal tissue disruption. The new MIGS platforms have demonstrated lower complication rates and improved patient comfort, resulting in a notable increase in their adoption among surgeons across the United States.

Artificial intelligence (AI)-powered diagnostic tools are being adopted by several medical provides into ophthalmology, since they help in the early detection of conditions such as diabetic retinopathy and age-related macular degeneration (AMD). As a result, AI-driven imaging systems and predictive analytics are expected to transform disease management further propelling the market expansion. For instance, in March 2025, Altris AI announced the launch of an advanced glaucoma Optic Disc Analysis module intended to aid in the early detection of the disease. The new artificial intelligence (AI) module builds upon an earlier innovation that utilizes Ganglion Cell Complex (GCC) Asymmetry Analysis that will enhance improvements from the Altris AI macula module, according to the news. 

The rising incidences of eye disorders like conjunctivitis, scleritis, and uveitis are driving demand for anti-inflammatory drugs. These medications are essential for controlling the pain and inflammation brought on by a number of eye conditions. Pharmaceutical companies are concentrating on creating sophisticated formulations with increased efficacy and fewer side effects as patients look for more effective treatment options. This growing demand presents a significant opportunity for the market expansion.

The rising popularity of online pharmacies is transforming the ophthalmic market by offering greater accessibility to medications such as eye drops, prescription drugs, and over-the-counter treatments. Online platforms are becoming more and more popular among consumers because of their ease of use, affordable prices, and wide selection of products. It is anticipated that this trend will continue, offering digital health retailers and pharmaceutical companies seeking to broaden their customer base a profitable growth path.

For instance, in January 2022, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced the European launch of the newest addition to its innovative portfolio of dry eye products – Systane Complete Preservative-Free Lubricant Eye Drops, now in an easy-to-use, multi-dose bottle.

“The United States ophthalmic market is expanding steadily, fueled by the growing incidence of chronic eye conditions such as glaucoma, retinal disorders, and dry eye syndrome, along with an aging population increasingly susceptible to these diseases,” states Mr. Ghanshyam Shrivastava, a senior healthcare analyst. “With a projected CAGR of 8.6% through 2032, heightened health awareness, increased healthcare spending, and improved access to diagnosis and treatment are driving strong demand for ophthalmic drugs and services.”

“The integration of artificial intelligence in diagnostics, the widespread adoption of remote patient monitoring (RPM), and the rise of minimally invasive surgical techniques are fundamentally transforming ophthalmic care delivery,” he adds. “Additionally, the rapid expansion of online and retail pharmacy channels is broadening consumer access to both prescription and OTC eye care products. Companies that invest in R&D, embrace digital health innovations, and focus on precision therapies will be best positioned to capitalize on the market’s accelerating trajectory.”